After MS onset, vitamin D3 supplementation has been reported to enhance regulatory T cells while reducing pro-inflammatory TH1 and TH17 cells, resulting in decreased IL-17 levels and increased IL-10 levels [59]. This evidence concerns the gene IL10 and myeloid sarcoma.